In the future evaluation of FAK inhibitor as a single targeting agent, the CRC population may be stratified by MYC, SRC, and YAP1, as there is a lack of strong overlap between FAK activation and the amplification or constitutive activation of SRC and YAP1 in the CRC population (Figure 1). The gene discussed is MYC; the disease is colorectal carcinoma.